# Hans J. Woerle

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hans-j-woerle/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,422 |
| Field | Diabetes Treatment and Management |
| h-index | 54 |
| i10-index | 83 |
| Last Known Institution | Boehringer Ingelheim (Germany) |
| OpenAlex ID | https://openalex.org/A5056064349 |
| ORCID iD | https://orcid.org/0000-0003-2595-1411 |
| Works | 102 |

## Researcher papers

- [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/)
- [Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus](https://scholariq.org/papers/renal-hemodynamic-effect-of-sodium-glucose-cotransporter-2-inhibition-in/)
- [Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk](https://scholariq.org/papers/effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with/)
- [Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-empagliflozin-added-to-existing-antidiabetes-treatment-in/)
- [Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes](https://scholariq.org/papers/effects-of-empagliflozin-on-blood-pressure-and-markers-of-arterial-stiffness-and/)
- [Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease](https://scholariq.org/papers/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus/)
- [Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial](https://scholariq.org/papers/effects-of-empagliflozin-on-risk-for-cardiovascular-death-and-heart-failure/)
- [Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes](https://scholariq.org/papers/initial-combination-of-empagliflozin-and-linagliptin-in-subjects-with-type-2/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

## Researcher university

- [Boehringer Ingelheim (Germany)](https://scholariq.org/institutions/boehringer-ingelheim-germany/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.